Case Report: Vitamin C Rapidly Reverses Pulmonary HTN Secondary to Scurvy
Ascorbic acid level testing confirmed severe deficiency (<0.1mg/dL).
Pulmonary Hypertension
Sotatercept Reduces Pulmonary Vascular Resistance in PAH
Decrease in pulmonary vascular resistance at 24 weeks greater with sotatercept versus placebo for pulmonary arterial hypertension
Tyvaso Approved for Pulmonary Hypertension With Interstitial Lung Disease
The sNDA approval is supported by data from the phase 3 INCREASE study that evaluated Tyvaso inhalation solution in 326 adults with PH-ILD.
Remunity Pump for Remodulin Now Available
Remunity Pump is intended for continuous subcutaneous delivery of Remodulin in prefilled cassettes for the treatment of PAH in adults aged ≥22 years.
Pulmonary Hypertension May Increase In-Hospital Mortality in Acute COPD Exacerbations
Pulmonary hypertension is associated with higher in-hospital mortality, morbidity, length of stay, and health care utilization in patients admitted to the hospital with an acute exacerbation of COPD.
Treprostinil Under Review for Pulmonary HTN With Interstitial Lung Disease
The sNDA is supported by data from the multicenter, double-blind, placebo-controlled phase 3 INCREASE study.
Inhaled Dry-Powder Form of Treprostinil Improves QoL in Pulmonary Arterial Hypertension
Treatment with LIQ861, an inhaled dry-powder form of treprostinil, was associated with significant improvements in several clinical and quality of life measures in patients with pulmonary arterial hypertension.
At-Home Use of Inhaled Nitric Oxide for Pulmonary HTN Complicated by COVID-19
Treatment with inhaled nitric oxide has been shown to have both pulmonary and antiviral benefits.
Inhaled Nitric Oxide at Higher Dose Improves Activity in PH Associated With ILD
Inhaled nitric oxide 45 mcg/kg of ideal body weight per hour was effective for improving physical activity in patients at risk for pulmonary hypertension associated with fibrotic interstitial lung disease.
Inhaled Nitric Oxide Therapy Evaluated in Preterm Neonates With Pulmonary Hypertension
Mallinckrodt announced that the phase 4 observational registry study evaluating INOmax® (nitric oxide) gas, for inhalation, in preterm neonates with pulmonary hypertension was stopped early due to “achievement of the pre-specified primary outcome measure, noninferiority.”
